Trials / Completed
CompletedNCT02943460
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of cilofexor in adults with primary sclerosing cholangitis (PSC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilofexor | Tablet(s) administered orally once daily with food |
| DRUG | Placebo to match cilofexor | Tablet(s) administered orally once daily with food |
Timeline
- Start date
- 2016-11-29
- Primary completion
- 2018-02-28
- Completion
- 2020-05-18
- First posted
- 2016-10-24
- Last updated
- 2021-06-07
- Results posted
- 2019-03-12
Locations
23 sites across 4 countries: United States, Austria, Canada, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02943460. Inclusion in this directory is not an endorsement.